Executive Summary

The long-term stability of plasmid DNA is a primary parameter in Chemistry, Manufacturing, and Controls (CMC) for viral vectors. A robust stability program for plasmid starting materials is a prerequisite for consistent AAV, lentivirus, and adenovirus production, directly influencing vector quality, titer, and the integrity of the final therapeutic product. Proactive characterization of plasmid integrity de-risks manufacturing campaigns and supports predictable IND timelines.

Establishing a Stability-Indicating Program for Plasmid DNA

The plasmid is the blueprint for a viral vector therapeutic. Its sequence and structural integrity dictate the fidelity of the final product. A comprehensive stability program is a core component of a phase-appropriate CMC strategy, established early in development. The objective is to define storage conditions and a re-test period by monitoring the quality attributes (QAs) of the plasmid over time.

A typical stability protocol involves subjecting qualified plasmid lots to their intended long-term storage conditions and pulling samples at predetermined intervals (e.g., 0, 3, 6, 12, 18, and 24 months). Each pull-point triggers a series of analytical tests designed to detect degradation.

Key stability-indicating assays include:

• Agarose Gel Electrophoresis (AGE): To visually assess the ratio of supercoiled, open-circular, and linear plasmid forms. A shift away from the supercoiled isoform is a primary indicator of degradation.

• Restriction Enzyme Digest Analysis: To confirm the plasmid’s identity and structural integrity. An expected banding pattern upon digestion demonstrates that the overall structure is intact.

• DNA Sequencing: To verify the genetic sequence of key regions, such as the inverted terminal repeats (ITRs), promoter, and transgene. This provides high-fidelity genomic intelligence for advanced therapeutics.

• Purity and Concentration: Measured via UV spectrophotometry (A260/A280) to ensure the material remains free of contaminants and that its concentration is stable.

The Link Between Starting Material Integrity and Long-Term In Vivo Outcomes

The requirement for a well-characterized, stable plasmid is underscored by clinical observations of long-term vector performance. Studies involving AAV-mediated gene transfer have demonstrated regulated, durable expression for over six years, a result that depends on the high fidelity of the initial vector construct [PMID: 15507527]. Likewise, long-term follow-up on adenovirus-based therapies has shown that durable clinical responses are possible, reinforcing the need for consistent manufacturing processes that begin with reliable starting materials [PMID: 16243818].

Managing these complex stability programs requires significant infrastructure. At Franklin Biolabs, our >100,000 sq ft of animal housing and specialized laboratory space provides the controlled environment necessary to execute these multi-year studies, ensuring our partners have a stable foundation for their entire preclinical and clinical journey.

A proactive approach to plasmid stability is fundamental to a successful CMC program. By defining the degradation profile of this raw material early, development teams can prevent costly delays, ensure batch-to-batch consistency, and build a robust data package to support an aggressive 18-24 month IND timeline.